New England Research & Management Inc. boosted its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 2.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,892 shares of the biopharmaceutical company’s stock after purchasing an additional 575 shares during the quarter. Bristol-Myers Squibb makes up 1.2% of New England Research & Management Inc.’s portfolio, making the stock its 18th biggest holding. New England Research & Management Inc.’s holdings in Bristol-Myers Squibb were worth $1,610,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BMY. State Street Corp increased its stake in Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after acquiring an additional 1,223,457 shares during the last quarter. Jennison Associates LLC increased its stake in Bristol-Myers Squibb by 0.8% during the first quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after acquiring an additional 178,436 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after acquiring an additional 2,451,390 shares during the last quarter. Legal & General Group Plc increased its stake in Bristol-Myers Squibb by 4.3% during the first quarter. Legal & General Group Plc now owns 8,213,428 shares of the biopharmaceutical company’s stock worth $446,664,000 after acquiring an additional 335,795 shares during the last quarter. Finally, Swiss National Bank increased its stake in Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after acquiring an additional 1,267,900 shares during the last quarter. Hedge funds and other institutional investors own 68.88% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/22/new-england-research-management-inc-has-1-61-million-position-in-bristol-myers-squibb-company-bmy.html.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded down 0.14% on Friday, reaching $63.24. The company had a trading volume of 1,553,271 shares. The company has a 50-day moving average price of $58.94 and a 200-day moving average price of $56.02. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $63.55. The firm has a market capitalization of $103.71 billion, a PE ratio of 23.10 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the business posted $0.69 earnings per share. Equities research analysts forecast that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.46%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

Several brokerages have commented on BMY. Credit Suisse Group set a $58.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Wednesday, August 16th. BMO Capital Markets restated an “underperform” rating and set a $47.00 price target (down from $51.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, July 26th. Leerink Swann dropped their price target on Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a research note on Friday, July 28th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Finally, Cowen and Company restated a “hold” rating and set a $65.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and an average price target of $62.20.

In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Theodore R. Samuels II purchased 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.